Scott Bessent’s Surprise Bond Move Helped, But Moderna Does the Heavy Lifting
The indices held up on one biotech breakthrough while the Nasdaq lost ground.
We’re Initiating New Positions in 2 ETFs
Following our cybersecurity strategy, we’re bringing new end-market exposures to the Portfolio.
Sticking With This Ocular Therapeutix Price Target as Key Treatment Moves Forward
The small-cap healthcare firm offered some encouraging earnings results.
Exiting This Healthcare Name Amid Surge
Locking in a nice double-digit gain and rebuilding cash along the way.
An Option Strategy for a Small-Cap Healthcare Name
Several insiders purchased just over 180,000 shares in total during mid-May, always a nice vote of confidence.
Why I Am Buying This Specialty Drug Stock
There is a relief bounce on an in-line CPI report, but the inflation issue isn’t going away.
We’re Tracking 29 Signals Across 9 Portfolio’s Investment Themes
Let’s scan through the headlines for the stories of the week that speak to our Pro Portfolio holdings.
Pockets of Momentum Endure as Traders Lean into Risk
I’m looking for hidden gems like this cancer treatment play following earnings.